Slides
Page 1
Sal Sai Life Sciences Investor Presentation August 07 , 2026 → Sai All rights reserved © 2026 Sai Life Sciences Limited
Page 2
Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements", These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. 2
Page 3
3 - Mr. Krishna Kanumuri MD & CEO We are pleased with the progress made during the quarter and the momentum we continue to see across the business. There is a clear evolution in what large pharmaceutical companies are looking for from their outsourcing partners. The expectation is for strong, scientifically led partners who can take greater ownership of integrated discovery and development programs, rather than simply execute individual pieces of work. We believe that the combination of our technology base, scientific talent and culture is a key reason why large pharmaceutical companies are increasingly bringing significant work to Sai through strategic engagements. These engagements will create a healthy and sustained pipeline over multiple years.
Page 4
4 We have begun FY27 on a healthy note, delivering revenue of ₹554 crore in Q1, up 12% year-on-year, with growth across both our CRO and CDMO businesses. CRO maintained strong momentum, growing 24% year-on-year, while our CMC pipeline continues to strengthen with 33 active commercial molecules and 14 late-phase molecules. Coupled with encouraging traction in our FTE-led engagement model, a healthy balance sheet and disciplined capital allocation, we remain confident in executing our long-term growth strategy. - Mr. Siva Chittor Whole-time Director & CFO
Page 5
Executive Summary
Page 6
Q1FY27 Quarterly Snapshot 6 Revenue ₹ 554 Cr 12% YoY Material Margin ₹ 409 Cr 15% YoY EBITDA ₹ 148 Cr 18% YoY PAT ₹ 73 Cr 22% YoY CDMO Revenue Mix 60 % CRO Revenue Mix 40 % Capacity Utilization 65 % Capex Incurred ₹ 263 Cr
Page 7
Consolidated Financial Highlights 7 Revenue (₹Cr) 496 554 Q1FY26 Q1FY27 * including forex Material Margin (₹Cr) & Margin (%) EBITDA* (₹Cr) & Margin (%) PAT (₹Cr) & Margin (%) 60 73 12% 13% Q1FY26 Q1FY27 125 148 25% 27% Q1FY26 Q1FY27 355 409 72% 74% Q1FY26 Q1FY27 12% YoY Growth 15% YoY Growth 18% YoY Growth 22% YoY Growth “The quarter reflects continued progress across both businesses and our longer-term strategic priorities. We remain confident in our ability to sustain our long-term revenue growth guidance of 15-20% and EBITDA range of 28–30%.”
Page 8
Business Updates 8 DISCOVERY • Grew by 24% YoY • Strengthening large pharma collaborations • Integrated service delivery with 65% of customers • Expect to extend integrated service offering to large pharma collaborations CMC • Production commenced for 3 of the 4 molecules added to the pipeline last year • Expanded a top-tier pharma relationship into an end to end collaboration spanning discovery to commercial. • FTE engagements beginning to contribute late phase assets KEY PRIORITIES AHEAD • Establishing an integrated peptide platform spanning discovery to manufacturing • Adding Drug Product facility to complement API development • Building a future-ready scientific organization through leadership development, campus engagement and Sai Academy Over 90% Pipeline Visibility on FY27 Targets
Page 9
Other Business Updates 9 • Achieved EcoVadis Platinum Rating 2026, placing Sai Life Sciences among the top 1% of companies globally assessed for sustainability performance. • Capex progress largely on schedule • Operationalized a new 100,000 sq. ft. R&D facility at Genome Valley, Hyderabad • Successfully executed commercial-scale Photo Flow Chemistry for a late-phase innovator program, further strengthening continuous processing capabilities. • High-Throughput Experimentation (HTE) platform commissioned at Hyderabad R&D campus to enable faster route scouting, process optimization and scale-up decisions.
Page 10
Company Overview
Page 11
Sai Life Sciences: At a Glance 11 Founded in 1999, Sai Life Sciences has transformed into an integrated CRDMO, delivering value across the pharma lifecycle from early discovery to commercial manufacturing 27 Years of Expertise Trusted by 300+ global clients, including 19 of the top 25 global pharma companies across the US, UK, EU, and Japan Global Partner of Choice World-class R&D and manufacturing facilities across Hyderabad, Bidar, Manchester, and Boston Expansive Infrastructure Focused investments in next- gen modalities like Peptides, ADCs and Oligos; empowered by digital transformation, automation, and AI/ML to accelerate delivery and differentiation Innovation-Led Growth Integrated CRDMO Contract Research, Development and Manufacturing Organization Outsourcing partner to pharma innovators Offer complete services from drug discovery to manufacturing
Page 12
Key Highlights 12 Note: As on 31 March 2026; *In terms of market cap for CY 2025 over the last 5 years Fastest growing Indian CRDMO USFDA, PMDA 100% successful track record of regulatory inspections across our R&D and manufacturing facilities. for discovery, development and manufacturing One-stop platform Listed on the Indian Stock Exchanges in Dec 2024 NSE/BSE Diverse therapy areas Oncology, CNS, Metabolic diseases, Inflammation, Antivirals, Rare diseases and more Revenue growth over the last 5 years 26% CAGR Total employees 3,800+ Average tenure of large pharma relationships 11+ years Active NCE commercial molecules 34 Phase III/ pre-registration 11 Active customers across US, UK, EU, Japan 300+ of the largest pharmaceutical companies are customers 19/25* Programs advanced to candidate nomination/ IND or Phase I/II/III 50+ Molecules from discovery to market 5
Page 13
Our Growth Journey • Incorporated in 1999; began as a medicinal chemistry partner to US biotech firms • Expanded into Process R&D and small-scale manufacturing aligned with the needs of Biotechs clients • First USFDA approval of Unit IV • Expanded R&D (Unit II) to enable large-scale pharma CDMO services • Added 100 KL capacity at Unit IV • Animal facility received AAALAC accreditation • Cleared USFDA & PMDA audits at multiple sites • Integrated Biology services; becoming end-to-end Discovery partner • Added 120 KL (PB-07) and 170 KL (PB-08) blocks at Unit IV • Entered global markets: labs in Manchester & Boston • Commissioned Clean Room, Amidites, and HPAPI blocks at Unit IV • Strategic partnership with Schrödinger to enhance discovery science • Continued regulatory track record and expansion of global footprint • Listed on NSE & BSE • Opened U8 - MedChem block with 200 fume hood capacity • Broke ground for a new Process R&D Block at Unit 2 Hyderabad, doubling PRD capacity, and adding capabilities in early phase peptide development and clinical formulations • Building additional production capacity at Unit IV, Bidar and acquired land for new greenfield site in Choutuppal 1999 - 2008 2009 – 2013 2014 – 2018 2019 – 2023 2024 – Present Founding & Early Biotech Foray CDMO Pivot Biology Foray; CDMO Consolidation Globalization, Scaled-up Integrated CRDMO Increasing Capacity & Strengthening New-Age Modalities 13
Page 14
Global Presence 14 Research laboratories for discovery and development located near overseas innovation hubs in Greater Boston, US and Manchester, UK, complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India. Greater Boston, USA Exploratory Biology Lab in the Cambridge-Boston life sciences ecosystem. Bidar, India 700KL cGMP manufacturing, serving highly regulated markets - USA, UK, EU & Japan. Hyderabad, India Integrated R&D Campus in Genome Valley, India's premier life sciences cluster. Manchester, UK Process R&D Lab in Alderley Park,a major science and innovation hub. Strategically located to combine innovation access, client proximity, and cost efficiency Global Team Employees 3,800+ In R&D 2,000+ In Manufacturing 650+ In Quality 350+ Note: As on 31 March 2026
Page 15
A leading Integrated CRDMO 15 Sai Life Sciences operates as both a CRO and a CDMO, offering an end-to-end platform for global pharmaceutical and biotech companies Computational Chemistry Medicinal & Synthetic ChemistryBiology DMPK Toxicology in vivo Pharmacology Discovery Development Analytical R&D Process R&D Developability and Preformulation Formulation Development Discovery Process Chemistry Process Safety Process Engineering Manufacturing Site-to-site Tech Transfer Life-cycle management Commercial supplies Mid to late phase supplies Tox to early phase supplies Early Phase Scale-up Seamless Integration One-stop solution from research to commercial production Regulatory Excellence Compliant with global standards (US FDA, PMDA, COFEPRIS) Scalable & Flexible Supporting emerging biotech & leading pharma companies
Page 16
End-to-end Capabilities, Small Molecule Focus 16 From target ID & validation to IND Stage through Creative Chemistry, Complex Biology, DMPK & Toxicology. • Integrated Drug Discovery • Complex Chemical Synthesis • In vitro and in vivo pharmacology • Comprehensive ADME and PK profiling • Toxicology evaluation Complex chemical synthesis from development to commercialization. • Advanced labs for early, late phase and commercial delivery • Comprehensive analytical capabilities • Fully equipped process safety lab • Pilot plant and early phase delivery block • HPAPI (< 0.1µg/m3) capability • Technology platforms – Bio catalysis, Flow chemistry, Chemo catalysis, Continuous extraction, Continuous distillation • 700 KL Capacity with manufacturing Blocks • 80 Production trains • 0.25 – 12 KL reactor sizes • Containment level of 1 µg/m3 • 11 Clean Rooms of ISO – 8 (Class 100,000) • Sensitive reactions block • HPAPI (< 0.1µg/m3) block w/ 8 reactors • Lyophilization at pilot & commercial scale • High pressure block • Moisture sensitive block • Column chromatography & cryogenic reaction Discovery Development Manufacturing
Page 17
Discovery Services spanning the entire journey from Target Validation to IND 17 Make/Chemistry Test / Biology &DMPK Design Analyze Target Evaluation HIT ID Lead Candidate In vivo Pharmacology Toxicology Formulations Integrated services: Synthetic & Medicinal Chemistry, CADD, Biology, DMPK and Toxicology
Page 18
Discovery Services (CRO) 18 * Discovery services (including chemistry, biology and/or DMPK services) Consistent Revenue Growth (₹ Cr) Client Stickiness >65% Revenues from customers in FY23-26 who availed more than one Discovery services(*) Automation Focus on automation and scale in DMPK and biology, enabling us to handle large, integrated programs Modalities Expansion Expanding capabilities in ADCs, TPDs, Peptides, CGTs, Oligos, and more. 38% 48% 62% 52% FY25 FY26 Pharma Biotech Customer Split % 274 467 497 626 775 FY22 FY23 FY24 FY25 FY26
Page 19
Discovery Services: Scaling Innovation, Driving Impact 19 >65% of Discovery programs are now integrated, with active use of next-gen biology, automation, and AI to accelerate development and improve outcomes Technology advancements are transforming Sai’s Discovery platform into a scalable, high-value growth engine Expanded Core Capabilities Scaled Chemistry, Biology, DMPK, and In Vivo labs delivering faster, parallelized research Colocalized & Global Teams Hyderabad campus and Boston Biology Lab enable seamless collaboration and rapid tech transfer Tech-Enabled Drug Discovery AI-enabled retrosynthesis tools High-throughput Experimentation DMPK automation CADD in silico tools Specialized Modalities Peptides, ADC payloads, Oligos, TPDs and driving high-value Discovery growth Next-Gen Preclinical Models Organoids and spheroids enable predictive, FDA- aligned efficacy and toxicity testing
Page 20
Development Services from H2L to Commercial Supply 20 • Discovery Process Chemistry • API Developability • Supply Route Optimization • API Developability • Commercial Route Selection • Control Strategy Definition • Continuous Verification • Continuous Improvement Hit 2 Lead Pre-Clinical Phase 1 Phase 2 Phase 3 Process Validation Commercial Supply Lifecycle Strategy Chemistry & Analytical Toolboxes and Supply Capability Underpinned by integrated scientific approaches applied in a phase-appropriate manner • Process Optimization & Design
Page 21
CMC Services (CDMO) • End-to-End capabilities from IND through to commercialization • Focus on Complex Chemistry, ADC Payloads & Linkers • Modern, GMP-compliant facilities across UK and India • Flexibility to support both small-scale clinical supplies and large-scale commercial production • Proven track record of commercializing NCEs • Robust regulatory record with USFDA and PMDA • 155 Programs in the pipeline across multiple therapy areas • Clear Regulatory Record: USFDA, PMDA • At the forefront of digitalization, automation and sustainability Business Mix Revenue Contribution – By Therapy (%) – FY26 Note: Therapy area contribution varies year-to-year based on client portfolio mix and project timelines. Not indicative of overall market trends Consistent Revenue Growth (₹ Cr) 7% 7% 25% 1% 2% 4% 16% 8% 15% 15% Anti Histamine Cardiovascular CNS Dermatology Genetic Disorders Immunology Infectious Diseases Metabolic Disorders Oncology Others 91% 94% 9% 6% FY25 FY26 Pharma Biotech Customer Split % 21 596 760 968 1,068 1,417 FY22 FY23 FY24 FY25 FY26
Page 22
New Modalities: Fortifying foundation to build scale 22 4% 3% 3% 7% 4% FY22 FY23 FY24 FY25 FY26 New Modalities Revenue Contribution (%) Peptides Complement peptide discovery with process and scale-up facilities for clinical supplies; focus on commercial supply of fragments before evolving to full-scale peptide manufacturing. Antibody-Drug Conjugates Enhancing conjugation in Discovery; upgrading to class 6 containment for end-to-end support. Evaluating clinical conjugation and fill-finish for clinical supply Oligonucleotides Involved in multiple projects with Pharma from development to commercial; to focus only on making amidites. Lipids Involved in supplying lipids for last few years; looking to expand capacity
Page 23
Our Strengths
Page 24
Information Technology - Driven Excellence: Digitization & Beyond Digitization 2017 onwards Digitalization 2022 onwards Digital Transformation 2023 onwards Converting data, documents and processes from paper/ analog to digital integration of digital technologies into all aspects of business operations Use of digitized data for effective monitoring through visual interactive dashboards. • GMP Pro and ELN implementation • QR Code & Label Management • Learning Management System • Audit Management System • Laboratory Information Management System • Validation Life Cycle Management System • Batch Quality, Yield, Experiments, Equipment Occupancy, Staffing status, QMS, etc. • Digital Transformation Initiatives • AI/ML - Manufacturing Process Prediction Model R&D and Mfg processes progressively digitized to 85% levels of digitization Interactive Business Intelligence dashboards created using real-time data across functions and use cases. Leveraging large data sets with AIML models to create prediction models. Looking Ahead • Digitization process in manufacturing expected to be complete by CY 2027 • Continued adoption of BI models to aid faster decision-making • AI/ML model proof-of-concept outcome to emerge in CY2026. • Based on results, further integration into operations will be undertaken. 24
Page 25
Global-Standard Operations, End-to-End Quality Assurance • 300+ QA/QC professionals across sites • Integrated e-systems: LIMS, e- QMS • QA independent; reports to CEO • Audited by USFDA, EMA, PMDA, Indian regulators • Focus on data integrity & global compliance Sustainability Leadership • 100% renewable energy at Bidar site • Zero Liquid Discharge: water- neutral ops • Carbon roadmap approved by SBTi • Low-emission logistics via DHL Safety & EHS Leadership • Embedded Process Safety from quote to execution phase; rigorous lifecycle safety assessments. • Plant Intermediates areas & lab fume cupboards validated down to 1 µcg/ m3 containment • First Indian company to join the PSCI membership; >30 PSCI Audits over the past 7 years • Silver rating by EcoVadis 25
Page 26
Annexure
Page 27
Consolidated Statement of Profit and Loss 27 Particulars (₹ Cr) Q1FY27 Q4FY26 Q1FY26 Revenue from operations 554 602 496 Other income 4 3 6 Total income 558 605 502 Expenses Cost of materials consumed and changes in inventories 145 162 141 Employee benefits expense 180 187 161 Other expenses 80 77 74 Forex (gain)/loss 1 (12) (4) EBITDA 148 189 125 EBITDA Margin 27% 31% 25% Finance costs 8 8 12 Depreciation and amortisation expense 46 45 38 Profit before tax & exceptional Item 98 139 81 Exceptional Item, loss - 0 - Profit before tax 98 139 81 Tax expense 25 35 20 Profit after tax 73 104 60
Page 28
Awards Certificates & Accreditations 28 Accelerating the Discovery, Development and Manufacturing of small molecules ISO 14001:2015, ISO 45001:2018, ISO 50001:2018, ISO 27001:2022 & ISO 28000:2022 certifications Certificate of Registration: Information Security Management System – ISO/IEC 27001:2013 Eco Vadis Silver Medal for Sustainability Member of: Bayer Supplier Decarbonization Award 2025 Finalist Signatory of United Nations Global Compact (UNGC) Certified for Social Accountability and ethical workplace practices GSK’s Environmental Sustainability Supplier award 2021 in the ‘Primary Manufacturing’ category
Page 29
Glossary 29 APIs Active pharmaceutical ingredients Biotechs Biotechnology companies, often referred to as biotech companies, are largely startups in the pharmaceutical sector which typically focus on developing innovative drugs and drug development technologies to address unmet medical needs Blockbuster End Molecules Blockbusters are drug products with annual sales of over US$1 billion in the Financial Year 2023 CDSCO Central Drug Standards Control Organization, India CMC / CDMO Chemistry, Manufacturing and Control / Contract Development and Manufacturing Organization CMO Contract Manufacturing Organization COFEPRIS Mexico Federal Commission for the Protection against Sanitary Risk of Mexico CRDMO Contract Research, Development, And Manufacturing Organization CRO Contract Research Organization DMPK Drug metabolism and pharmacokinetics GATT General Agreement on Tariffs and Trade Generic drugs Refer to pharmaceutical drugs that have the same chemical composition as the original innovator drug and can be sold by companies after the patent on the original drug expires Innovation Clusters/Hubs Nine regions identified by Frost and Sullivan including Boston/Cambridge in Massachusetts, Manchester/London/Cambridge in UK, Chicago in Illinois, New Jersey, New York, Paris in France, Switzerland and Japan. In 2022, approximately 57% of global R&D spending were in these nine pharma hubs Innovator Drugs Refer to first drugs created containing specific active ingredients and undergo approval or patent process for use Large Molecule Have a large molecular weight and made of proteins that are complex in structure compared to small molecule drugs. Costly to manufacture and, at this time, in most cases can only be administered by injection or infusion. Typically manufactured biologically, i.e. extracted from living organisms, but often include certain synthetic chemistry processes Large Pharma Companies Pharma companies with revenues > USD 10 billion Mid Pharma Companies Pharma companies with revenues in range of USD 500 million to USD 10 billion NCE New chemical entities PMDA Pharmaceuticals and Medical Devices Agency, Japan Small Molecule Organic compound with low molecular weight, small molecule drugs are known for their affordability, ease of administration (largely orally), and broad therapeutic coverage. Typically manufactured using synthetic chemistry processes Small Pharma Companies Pharma companies with revenues lower than USD 500 million TRIPS Trade-Related Aspects of Intellectual Property Rights UNIT IV Manufacturing facility at Bidar USFDA United States Food and Drug Administration
Page 30
© Sai Life Sciences Limited. L4, SLN Terminus, Gachibowli, Hyderabad 500032, Telangana, India. For more details please contact: Investorrelation@sailife.com Thank You